Sanofi | Balance Sheet

Fiscal year is January-December. All values EUR Millions.
2013
2014
2015
2016
2017
2018
Cash & Short Term Investments
8,442
7,559
9,246
10,381
10,448
6,925
Total Accounts Receivable
8,854
9,010
8,853
9,050
8,675
9,345
Inventories
6,352
6,562
6,516
6,892
6,816
7,477
Other Current Assets
264
296
313
364
413
832
Total Current Assets
23,912
23,427
24,928
26,687
26,352
24,579
Net Property, Plant & Equipment
10,182
10,396
9,943
10,019
9,579
9,651
Total Investments and Advances
4,583
4,189
4,681
4,904
5,444
5,550
Long-Term Note Receivable
676
711
671
776
730
620
Intangible Assets
52,529
53,740
51,583
51,166
53,344
66,124
Other Assets
29
69
5,801
6,451
87
271
Total Assets
96,055
97,392
102,321
104,672
99,826
111,408
ST Debt & Current Portion LT Debt
4,176
1,538
3,436
1,764
1,275
Accounts Payable
3,003
3,651
3,817
4,297
4,633
Income Tax Payable
978
948
1,044
1,134
1,180
Other Current Liabilities
5,771
6,895
8,528
9,239
8,369
Total Current Liabilities
13,928
13,032
16,825
16,434
15,457
Long-Term Debt
10,414
13,276
13,118
16,815
14,326
Provision for Risks & Charges
8,637
9,434
8,894
8,618
8,104
Deferred Taxes
916
755
1,819
2,377
2,685
Other Liabilities
983
1,277
2,379
2,789
2,076
Total Liabilities
39,022
41,124
44,111
46,948
41,568
Common Equity (Total)
56,904
56,120
58,049
57,554
58,089
Total Shareholders' Equity
56,904
56,120
58,049
57,554
58,089
Total Equity
57,033
56,268
58,210
57,724
58,258
Liabilities & Shareholders' Equity
96,055
97,392
102,321
104,672
99,826
Accumulated Minority Interest
129
148
161
170
169

About Sanofi

View Profile
Address
54, rue La Boétie
Paris Ile-de-France 75008
France
Employees -
Website http://www.sanofi.com
Updated 07/08/2019
Sanofi engages in the research, production and distribution of pharmaceutical products. It operates through the following business segments: Pharmaceuticals, Consumer Healthcare, and Human Vaccines. The Pharmaceuticals segment comprises the commercial operations of the following global franchises: specialty care, diabetes & cardiovascular, established prescription products and generics, together with research, development and production activities.